申请人:Vanderbilt University
公开号:US20180028501A1
公开(公告)日:2018-02-01
Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M
4
(mAChR M
4
). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
本文披露了硫代噻吩[3,2-e][1,2,4]三氮唑[1,5-a]吡啶-6-胺,硫代噻吩[3,2-e][1,2,4]三氮唑[4,3-a]吡啶-3-胺和咪唑[1,2-a]硫代噻吩[3,2-e]吡啶-3-胺化合物,这些化合物可能作为肌胆碱受体M4(mAChR M4)的正向变构调节剂而有用。本文还披露了制备这些化合物的方法,包括这些化合物的药物组合物,以及使用这些化合物和组合物治疗与肌胆碱受体功能障碍相关的神经和精神疾病的方法。